Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

ClinicalTrials.gov ID: NCT03343197

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03343197. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.

Study identification

NCT ID: NCT03343197
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Institut de Recherches Internationales Servier; Other
Enrollment: 49 participants

Conditions and interventions

Conditions

Glioma

Interventions

AG-120 Drug
AG881 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 20, 2018 (Actual)
Primary completion: Aug 2, 2019 (Actual)
Completion: Mar 28, 2025 (Actual)
Last update posted: Feb 17, 2026

2018 – 2025

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
United States, California	Los Angeles	California	90024	—
United States, California	San Francisco	California	94143	—
United States, Massachusetts	Boston	Massachusetts	02215	—
United States, New York	New York	New York	10065	—
United States, North Carolina	Durham	North Carolina	27710	—
United States, Texas	Dallas	Texas	75390	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03343197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 17, 2026 · Synced Nov 15, 2026